Pharmacy First Evaluation

  • Research type

    Research Study

  • Full title

    Pharmacy First Evaluation: Impact on Healthcare Usage, Antimicrobial use and Safety

  • IRAS ID

    355949

  • Contact name

    Kimberley Sonnex

  • Contact email

    kimberley.sonnex@nottingham.ac.uk

  • Sponsor organisation

    University of Nottingham

  • Duration of Study in the UK

    1 years, 7 months, 30 days

  • Research summary

    The Covid-19 pandemic has caused a significant backlog in hospital care, contributing to an increased demand for GP appointments. In response, under the Government’s NHS Primary Care Recovery Plan, NHS England (NHSE) commissioned the Pharmacy First (PF) service, launched in February 2024. Part of Pharmacy first is a clinical pathways service to assess and manage seven common conditions, including the supply of prescription only medicines where appropriate, after consultation with a community pharmacist.
    The service aims to enable patients to access care in quicker and more convenient ways, which aims to relieve some of the pressures on both general practices and hospitals.
    We will assess what effect the introduction of the service has had on GP appointment and hospital use associated with each of the seven conditions. We will look how these changed alongside the increase in recorded PF consultations, and rates of PF in England. We will also look at how changes in the number of consultations at general practices and hospitals was affected by deprivation, ethnicity, age, gender, geographical region, and the patient's number of other health conditions.

    The treatment of conditions included in Pharmacy First utilises antimicrobial medications; there is concern that the new service could increase the supply of these medications and lead to resistance. We will evaluate any change in the number of prescriptions for these antimicrobials after the introduction of the service.

    Finally, the safety of the Pharmacy First service will also be evaluated. We will evaluate if patients are having adverse effects, such as hospitalisation for the conditions being treated, after the introduction of the Pharmacy First service

  • REC name

    Wales REC 3

  • REC reference

    25/WA/0167

  • Date of REC Opinion

    28 May 2025

  • REC opinion

    Favourable Opinion